Clinical Trials - May 12, 2014
Bioarctic starts Alzheimer study in Sweden
Bioarctic Neuroscience has announced that the first patients in Sweden have been treated with BAN2401 in a clinical study for patients with an early type of Alzheimer’s disease. BAN2401 is a monoclonal antibody that has been developed in the laboratory of Professor Lars Lannfeldt at Uppsala University. The study is carried out by the Japanese […]
Clinical Trials - May 12, 2014
Amgen and AstraZeneca announce positive results from psoriasis study
The two companies have announced positive results from Phase III study of brodalumab (AMG 827) in patients with moderate-to-severe plaque psoriasis. According to AstraZeneca, the study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. Primary endpoints were patients achieving at least a 75 percent improvement from baseline […]
In a new job - May 9, 2014
Anders Ekblom joins board at Medivir
As the company recently held its annual general meeting a new chairman was elected as well as three new members, including Anders Ekblom, former CEO at AstraZeneca AB. Niklas Prager, former CEO at Pfizer AB and Bertil Samuelsson, former Chief Scientific Advisor at Medivir, also were elected into the board. Anders Hallberg, Anna Malm Bernsten, Björn […]
Clinical Trials - May 9, 2014
Oncos Therapeutics presents achievement in cancer immunotherapy
The clinical stage biotechnology company has presented data on its lead compound, ONCOS-102. The data, presented in two separate podium presentations on May 7th and 8th at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT) in Mainz, Germany, demonstrated that local administration of ONCOS-102 is able to induce a systemic, tumor-specific immune response in late-stage cancer […]
Clinical Trials - May 9, 2014
AstraZeneca starts phase III immunotherapy study
The study is a a phase III programme for MEDI4736, an immunotherapy in development for the treatment of non-small cell lung cancer (NSCLC) and other cancers. MEDI4736 is a human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumours avoid detection by the immune system. MEDI4736 blocks these signals, […]
Acquisition - May 8, 2014
Lundbeck acquires Chelsea Therapeutics
H. Lundbeck A/S entered into a definitive agreement under which Lundbeck will commence a tender offer to acquire Chelsea Therapeutics International, Ltd. Under the agreement, Lundbeck will gain rights to the FDA-approved product droxidopa with expected launch during 2014. Lundbeck is offering USD 658 million. The total potential consideration represents an attractive premium of 59% over the closing […]
